Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 169Lymphoid 118Myeloid 109Plasma cell 55Classical hematology 47Sarcoma 25Dermatologic 13CNS 10Other neoplasm 4Genitourinary 2Breast 2Tumor-Agnostic 1Thoracic 1

Conditions

Thymoma 1Myelodysplastic Syndromes 1Leukemia 1Graft vs Host Disease 1Anemia, Refractory 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Busulfan × Thoracic × Clear all
NCT00003662 2011-03-07

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Roswell Park Cancer Institute

Phase 2 Completed
90 enrolled
Classical hematologyMyeloidOther hematologic neoplasmThoracic

Anemia, Refractory, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡